Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages

  Geoghegan, James C ^a   Keiser, Nicholas W ^a   Okulist, Anna ^a   Martins, Inês ^a   Wilson, Matthew S ^a   Davidson, Beverly L ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

AAV; brain vasculature; capsid engineering; chondroitin sulfate; endothelium; phage display; receptor

Indexed keywords

CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; DERMATAN SULFATE; HEPARAN; HEPARAN SULFATE; HEPARIN; HYALURONIC ACID; SIALIC ACID;

ADENO ASSOCIATED VIRUS; ADULT; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BINDING AFFINITY; BRAIN BLOOD VESSEL; BRAIN REGION; BRAIN TISSUE; BRAIN VASCULAR ENDOTHELIUM; CARBOHYDRATE ANALYSIS; CELL CULTURE; CELL SURFACE; CELLULAR DISTRIBUTION; CHO CELL LINE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; IN VITRO STUDY; IN VIVO GENE TRANSFER; LYSOSOME STORAGE DISEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRION; VIRUS ATTACHMENT;

EID: 84923266826     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.50     Document Type: Article

References (52)

1. Asokan, A, Schaffer, DV and Samulski, RJ (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 20: 699-708.
2. Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM and Kaspar, BK (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27: 59-65.
3. Yang, B, Li, S, Wang, H, Guo, Y, Gessler, DJ, Cao, C et al. (2014). Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther 22: 1299-1309.
4. Girod, A, Ried, M, Wobus, C, Lahm, H, Leike, K, Kleinschmidt, J et al. (1999). Genetic capsid modifcations allow effcient re-targeting of adeno-associated virus type 2. Nat Med 5: 1438.
5. Grifman, M, Trepel, M, Speece, P, Gilbert, LB, Arap, W, Pasqualini, R et al. (2001). Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 3: 964-975.
6. Nicklin, SA, Buening, H, Dishart, KL, de Alwis, M, Girod, A, Hacker, U et al. (2001). Effcient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 4: 174-181.
7. Chen, YH, Chang, M and Davidson, BL (2009). Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15: 1215-1218.
8. Sleat, DE, Wiseman, JA, El-Banna, M, Kim, KH, Mao, Q, Price, S et al. (2004). A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J Neurosci 24: 9117-9126.
9. Sleat, DE, Donnelly, RJ, Lackland, H, Liu, CG, Sohar, I, Pullarkat, RK et al. (1997). Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277: 1802-1805.
10. Balestrieri, ML and Napoli, C (2007). Novel challenges in exploring peptide ligands and corresponding tissue-specifc endothelial receptors. Eur J Cancer 43: 1242-1250.
11. Rajotte, D and Ruoslahti, E (1999). Membrane dipeptidase is the receptor for a lungtargeting peptide identifed by in vivo phage display. J Biol Chem 274: 11593-11598.
12. Daquinag, AC, Zhang, Y, Amaya-Manzanares, F, Simmons, PJ and Kolonin, MG (2011). An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell 9: 74-86.
13. Brown, RC, Morris, AP and O'Neil, RG (2007). Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 1130: 17-30.
14. Montesano, R, Pepper, MS, Möhle-Steinlein, U, Risau, W, Wagner, EF and Orci, L (1990). Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62: 435-445.
15. Kaludov, N, Brown, KE, Walters, RW, Zabner, J and Chiorini, JA (2001). Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and effcient transduction but differ in sialic acid linkage specifcity. J Virol 75: 6884-6893.
16. Wu, Z, Miller, E, Agbandje-McKenna, M and Samulski, RJ (2006). Alpha2, 3 and alpha2, 6 N-linked sialic acids facilitate effcient binding and transduction by adeno-associated virus types 1 and 6. J Virol 80: 9093-9103.
17. Robertson, MA, Etchison, JR, Robertson, JS, Summers, DF and Stanley, P (1978). Specifc changes in the oligosaccharide moieties of VSV grown in different lectin-resistnat CHO cells. Cell 13: 515-526.
18. Tecedor, L, Stein, CS, Schultz, ML, Farwanah, H, Sandhoff, K and Davidson, BL (2013). CLN3 loss disturbs membrane microdomain properties and protein transport in brain endothelial cells. J Neurosci 33: 18065-18079.
19. Summerford, C and Samulski, RJ (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438-1445.
20. Perabo, L, Goldnau, D, White, K, Endell, J, Boucas, J, Humme, S et al. (2006). Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol 80: 7265-7269.
21. Kern, A, Schmidt, K, Leder, C, Müller, OJ, Wobus, CE, Bettinger, K et al. (2003). Identifcation of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 77: 11072-11081.
22. White, SJ, Nicklin, SA, Büning, H, Brosnan, MJ, Leike, K, Papadakis, ED et al. (2004). Targeted gene delivery to vascular tissue in vivo by tropism-modifed adeno-associated virus vectors. Circulation 109: 513-519.
23. Esko, JD, Stewart, TE and Taylor, WH (1985). Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci USA 82: 3197-3201.
24. Esko, JD, Rostand, KS and Weinke, JL (1988). Tumor formation dependent on proteoglycan biosynthesis. Science 241: 1092-1096.
25. Kingsley, DM, Kozarsky, K F, Hobbie, L and Krieger, M (1986). Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNAc 4-epimerase defcient mutant. Cell 44: 749-759.
26. Schultz, ML, Tecedor, L, Chang, M and Davidson, BL (2011). Clarifying lysosomal storage diseases. Trends Neurosci 34: 401-410.
27. Muenzer, J (2011). Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 50 (suppl. 5): v4-12.
28. Liu, G, Martins, I, Wemmie, JA, Chiorini, JA and Davidson, BL (2005). Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci 25: 9321-9327.
29. Chen, YH, Clafin, K, Geoghegan, JC and Davidson, BL (2012). Sialic acid deposition impairs the utility of AAV9, but not peptide-modifed AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther 20: 1393-1399.
30. Gandhi, NS and Mancera, RL (2008). The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72: 455-482.
31. Zimmermann, DR and Dours-Zimmermann, MT (2008). Extracellular matrix of the central nervous system: from neglect to challenge. Histochem Cell Biol 130: 635-653.
32. Pasqualini, R and Ruoslahti, E (1996). Organ targeting in vivo using phage display peptide libraries. Nature 380: 364-366.
33. Rajotte, D, Arap, W, Hagedorn, M, Koivunen, E, Pasqualini, R and Ruoslahti, E (1998). Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102: 430-437.
34. Arap, W, Kolonin, MG, Trepel, M, Lahdenranta, J, Cardó-Vila, M, Giordano, RJ et al. (2002). Steps toward mapping the human vasculature by phage display. Nat Med 8: 121-127.
35. Misinzo, G, Delputte, PL, Meerts, P, Lefebvre, DJ and Nauwynck, HJ (2006). Porcine circovirus 2 uses heparan sulfate and chondroitin sulfate B glycosaminoglycans as receptors for its attachment to host cells. J Virol 80: 3487-3494.
36. Bergefall, K, Trybala, E, Johansson, M, Uyama, T, Naito, S, Yamada, S et al. (2005). Chondroitin sulfate characterized by the E-disaccharide unit is a potent inhibitor of herpes simplex virus infectivity and provides the virus binding sites on gro2C cells. J Biol Chem 280: 32193-32199.
37. Argyris, EG, Acheampong, E, Nunnari, G, Mukhtar, M, Williams, KJ and Pomerantz, RJ (2003). Human immunodefciency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. J Virol 77: 12140-12151.
38. Sawada, R, Peterson, C Y, Gonzalez, AM, Potenza, BM, Mueller, B, Coimbra, R et al. (2011). A phage-targeting strategy for the design of spatiotemporal drug delivery from grafted matrices. Fibrogenesis Tissue Repair 4: 7 .
39. Pajusola, K, Gruchala, M, Joch, H, Lüscher, T F, Ylä-Herttuala, S and Büeler, H (2002). Cell-type-specifc characteristics modulate the transduction effciency of adeno-associated virus type 2 and restrain infection of endothelial cells. J Virol 76: 11530-11540.
40. Summerford, C, Bartlett, JS and Samulski, RJ (1999). AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 5: 78-82.
41. Holley, RJ, Deligny, A, Wei, W, Watson, HA, Niñonuevo, MR, Dagälv, A et al. (2011). Mucopolysaccharidosis type I, unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking a-l-iduronidase. J Biol Chem 286: 37515-37524.
42. Gray, SJ, Nagabhushan Kalburgi, S, McCown, TJ and Jude Samulski, R (2013). Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 20: 450-459.
43. Keiser, NW, Yan, Z, Zhang, Y, Lei-Butters, DC and Engelhardt, JF (2011). Unique characteristics of AAV1, 2, and 5 viral entry, intracellular traffcking, and nuclear import defne transduction effciency in HeLa cells. Hum Gene Ther 22: 1433-1444.
44. Kaminsky, PM, Keiser, N W, Yan, Z, Lei-Butters, DC and Engelhardt, JF (2012). Directing integrin-linked endocytosis of recombinant AAV enhances productive FAK-dependent transduction. Mol Ther 20: 972-983.
45. Naumer, M, Popa-Wagner, R and Kleinschmidt, JA (2012). Impact of capsid modifcations by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction. J Gen Virol 93(Pt 10): 2131-2141.
46. Bobardt, MD, Salmon, P, Wang, L, Esko, JD, Gabuzda, D, Fiala, M et al. (2004). Contribution of proteoglycans to human immunodefciency virus type 1 brain invasion. J Virol 78: 6567-6584.
47. Yamamoto, C, Deng, X, Fujiwara, Y and Kaji, T (2005). Proteoglycans predominantly synthesized by human brain microvascular endothelial cells in culture are perlecan and biglycan. J Health Sci 51: 576-583.
48. Awano, T, Katz, ML, O'Brien, D P, Sohar, I, Lobel, P, Coates, JR et al. (2006). A frame shift mutation in canine TPP1 (the ortholog of human CLN2) in a juvenile Dachshund with neuronal ceroid lipofuscinosis. Mol Genet Metab 89: 254-260.
49. Urabe, M, Ding, C and Kotin, RM (2002). Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 13: 1935-1943.
50. Smith, RH, Levy, JR and Kotin, RM (2009). A simplifed baculovirus-AAV expression vector system coupled with one-step affnity purifcation yields high-titer rAAV stocks from insect cells. Mol Ther 17: 1888-1896.
51. Farndale, RW, Buttle, DJ and Barrett, AJ (1986). Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 883: 173-177.
52. Song, L and Pachter, JS (2003). Culture of murine brain microvascular endothelial cells that maintain expression and cytoskeletal association of tight junction-associated proteins. In Vitro Cell Dev Biol Anim 39: 313-320.